Table 2.
Comparison of clinical and laboratory parameters at baseline and after 3-month treatment with tofacitinib and csDMARDs.
| Before, median (IQR) | After 3 months, median (IQR) | p | |
|---|---|---|---|
| Swollen joint count, 0-46 | 7 (6-9) | 2 (0-3) | <0.001 |
| Tender joint count, 0-46 | 11 (5-17) | 1 (0-8) | <0.001 |
| Swollen joint count, 0-28 | 5 (4-7) | 1 (0-2) | <0.001 |
| Tender joint count, 0-28 | 4 (2-10) | 1 (0-3) | <0.001 |
| General health, VAS, 0-100 mm | 51 (37-65) | 16 (7-29) | 0.001 |
| Pain, VAS, 0-100 mm | 43 (22-64) | 12 (5-38) | 0.002 |
| Physician’s assessment, VAS, 0-100 mm | 35 (31-46) | 13 (11-18) | <0.001 |
| HAQ disability index, 0-3 | 0.813 (0.625-1.253) | 0.130 (0-0.813) | 0.011 |
| DAS28 | 4.4 (3.6-4.9) | 2.6 (1.9-2.9) | <0.001 |
| Plasma C-reactive protein, mg/l | 5 (3-17) | 3 (3-4) | 0.042 |
| Blood hemoglobin, g/l | 129 (126-140) | 132 (126-145) | 0.775 |
| Blood leukocyte count, ×109/l | 8.3 (6.1-9.1) | 5.3 (4.3-6.9) | 0.003 |
| Blood neutrophil count, ×109/l | 5.32 (4.02-6.34) | 2.88 (2.32-3.91) | 0.003 |
| Blood lymphocyte count, ×109/l | 1.40 (1.07-1.94) | 1.41 (1.20-1.83) | 0.959 |
| Blood platelet count, ×109/l | 297 (274-334) | 281 (225-302) | <0.001 |
| Plasma alanine aminotransferase, U/l | 20 (15-26) | 21 (19-28) | 0.224 |
| Plasma creatinine, µmol/l | 63 (56-83) | 68 (56-86) | 0.615 |
p-values are calculated using Wilcoxon test and shown in bold when p ≤ 0.05.
DAS28, composite Disease Activity Score for 28 joints based on the C-reactive protein level (DAS28-4[CRP]); csDMARD, conventional systemic disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; IQR, interquartile range; VAS, visual analogue scale.